Literature DB >> 31600033

Cytologic evaluation of p16 staining in head and neck squamous cell carcinoma in CytoLyt versus formalin-fixed material.

Darren J Buonocore1, Evan Fowle1,2, Oscar Lin1, Bin Xu1, Nora Katabi1, Jean-Marc Cohen1.   

Abstract

BACKGROUND: The management of high-risk human papillomavirus (HR-HPV)-related oropharyngeal head and neck squamous cell carcinomas (HNSCCs) are distinct from HNSCC linked to smoking and alcohol use. HR-HPV-positive HNSCC frequently presents as a cervical lymph node metastasis. Because fine-needle aspiration (FNA) is often the initial diagnostic procedure, evaluating HR-HPV status in cytology specimens is important. The overexpression of p16 is a surrogate for HR-HPV; however, the evaluation of p16 in FNAs remains controversial.
METHODS: From September 2015 to December 2016, cytopathologists performed 25 FNAs of neck lymph nodes that were suspicious for HR-HPV-positive HNSCC. Initial passes produced smears for on-site evaluation and CytoLyt material. Additional passes were formalin-fixed. A CytoLyt cell block (CCB) and a formalin-fixed cell block (FFCB) were prepared, and p16 immunocytochemistry was performed.
RESULTS: In 24 of 25 cases, the FFCB had diffuse (≥70% of cells), strong nuclear/cytoplasmic p16 staining. In all 24 of these cases, HR-HPV was detected by in situ hybridization. The corresponding CCB had weak-to-moderate p16 staining in <70% of cells (range, 5%-60% of cells) in 17 cases, 4 had weak-to-moderate diffuse staining, and 4 were acellular. The percentage of p16-positive cells was significantly higher with FFCB than with CCB (formalin: 94% ± 2%; CytoLyt, 38% ± 7%; 2-tailed, paired Student t test; P < .001; Fisher exact test, P < .001).
CONCLUSIONS: The fixative used had a drastic impact on p16 staining, which explained the staining variability reported in the literature. FFCBs show a diffuse staining pattern, which correlates with HR-HPV status, whereas CCBs show a weaker and inconsistent staining pattern, which is more difficult to interpret.
© 2019 American Cancer Society.

Entities:  

Keywords:  cytology; human papillomavirus (HPV); p16; squamous carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31600033      PMCID: PMC6906234          DOI: 10.1002/cncy.22191

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  17 in total

1.  Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block.

Authors:  Yun Gong; Xiaoping Sun; Claire W Michael; Sam Attal; Beth A Williamson; Carlos W M Bedrossian
Journal:  Diagn Cytopathol       Date:  2003-01       Impact factor: 1.582

2.  CytoLyt® fixation and decalcification pretreatments alter antigenicity in normal tissues compared with standard formalin fixation.

Authors:  Jennette R Gruchy; Penny J Barnes; Kelly A Dakin Haché
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-04

Review 3.  The role of cytology in the era of HPV-related head and neck carcinoma.

Authors:  Sinchita Roy-Chowdhuri; Savitri Krishnamurthy
Journal:  Semin Diagn Pathol       Date:  2014-12-19       Impact factor: 3.464

4.  Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists.

Authors:  James S Lewis; Beth Beadle; Justin A Bishop; Rebecca D Chernock; Carol Colasacco; Christina Lacchetti; Joel Todd Moncur; James W Rocco; Mary R Schwartz; Raja R Seethala; Nicole E Thomas; William H Westra; William C Faquin
Journal:  Arch Pathol Lab Med       Date:  2017-12-18       Impact factor: 5.534

5.  Novel Modification of HistoGel-Based Cell Block Preparation Method: Improved Sufficiency for Molecular Studies.

Authors:  Natasha Rekhtman; Darren J Buonocore; Dorota Rudomina; Maria Friedlander; Crisbane Dsouza; Gitika Aggarwal; Maria Arcila; Marcia Edelweiss; Oscar Lin
Journal:  Arch Pathol Lab Med       Date:  2017-11-02       Impact factor: 5.534

6.  CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: Critical diagnostic implications.

Authors:  Darren J Buonocore; Fumiko Konno; Achim A Jungbluth; Denise Frosina; Mariam Fayad; Marcia Edelweiss; Oscar Lin; Natasha Rekhtman
Journal:  Cancer Cytopathol       Date:  2019-08-09       Impact factor: 5.284

7.  Disease-Specific Survival with Spindle Cell Carcinoma of the Head and Neck.

Authors:  Tristan C Bice; Van Tran; Mark A Merkley; Shawn D Newlands; Paul G van der Sloot; Shuang Wu; Matthew C Miller
Journal:  Otolaryngol Head Neck Surg       Date:  2015-07-22       Impact factor: 3.497

8.  Correlation of p16 immunohistochemistry in FNA biopsies with corresponding tissue specimens in HPV-related squamous cell carcinomas of the oropharynx.

Authors:  Jalal B Jalaly; James S Lewis; Brian T Collins; Xingyong Wu; Xiao-Jun Ma; Yuling Luo; Cory T Bernadt
Journal:  Cancer Cytopathol       Date:  2015-08-04       Impact factor: 5.284

9.  The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas.

Authors:  Jens Jakscha; Inti Zlobec; Claudio Storck; Ellen C Obermann; Luigi Tornillo; Luigi M Terracciano; Claude A Fischer
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05-16       Impact factor: 2.503

Review 10.  Tissue fixation and the effect of molecular fixatives on downstream staining procedures.

Authors:  William J Howat; Beverley A Wilson
Journal:  Methods       Date:  2014-02-21       Impact factor: 3.608

View more
  2 in total

1.  Quantitative assessment of p16 expression in FNA specimens from head and neck squamous cell carcinoma and correlation with HPV status.

Authors:  Rita Abi-Raad; Manju L Prasad; Syed Gilani; James Garritano; Deborah Barlow; Guoping Cai; Adebowale J Adeniran
Journal:  Cancer Cytopathol       Date:  2020-12-28       Impact factor: 5.284

Review 2.  Molecular Diagnostics in Human Papillomavirus-Related Head and Neck Squamous Cell Carcinoma.

Authors:  Katherine C Wai; Madeleine P Strohl; Annemieke van Zante; Patrick K Ha
Journal:  Cells       Date:  2020-02-22       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.